Alopecia Areata: An Overview of Current and Emerging Treatment Modalities

Abstract

Background: Alopecia areata (AA) is an autoimmune, non-scarring hair loss disorder characterized by an unpredictable clinical course and variable treatment responses. The primary goals of treatment are to arrest disease progression, promote hair regrowth, and prevent recurrence. Therapeutic approaches vary according to disease severity, extent, duration, and patient characteristics. Topical and intralesional corticosteroids are commonly used for localized disease, while topical immunotherapy, minoxidil, vitamin D analogues, and other topical agents may provide additional benefits. Extensive or rapidly progressive disease may require systemic treatments, including corticosteroids, methotrexate, cyclosporine, and azathioprine. Recent advances in understanding the immunopathogenesis of AA have introduced Janus kinase (JAK) inhibitors as targeted therapeutic options that interrupt inflammatory signaling pathways responsible for hair follicle damage. Additional therapeutic modalities include platelet-rich plasma, phototherapy, and microneedling, which may promote hair regrowth through immunomodulation, growth factor release, and stimulation of follicular activity. However, treatment selection remains challenging because of variable efficacy, potential adverse effects, and disease recurrence. Understanding the mechanisms, clinical applications, benefits, and limitations of available therapies is essential for developing individualized treatment strategies and improving clinical outcomes and patients' quality of life.